Kimia Biosciences share price & results
- Jun 2026
- Jun 2026
Gurugram (Haryana)-based manufacturer and marketer of Active Pharmaceutical Ingredients (bulk drugs) across anticoagulant, anti-diabetic, antihypertensive, antibiotic and other therapeutic segments.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 20.7 | −12.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 11.3 | +0.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 0.36 | −40.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 51.36 | +125.7 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 2.47 | −11.3 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | -6.73 | −16.7 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −11.2% 1Y
1Y: ₹33.86 on 24 Oct 2025 → ₹30.07. High ₹39.95 (13 Feb 2026), low ₹23.55 (30 Mar 2026).
- Previous close
- ₹30.83
- Market cap
- ₹169 Cr
- 52-week range
- ₹23.55 – ₹39.95
- One year
- −11.01%
- Price to earnings (TTM to Jun 2026)
- 23.50×
- Return on equity (TTM to Jun 2026)
- 51.36%
Overview
- Symbol
- NSE:KIMIABL
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What KIMIA BIOSCIENCES LIMITED does
Based on the company's own presentations, annual report and earnings calls.
Kimia Biosciences is engaged in the manufacture, marketing and trading of Active Pharmaceutical Ingredients (APIs)/bulk drugs and their intermediates, addressing a range of high-potential therapeutic segments. Product is manufactured on a job-work basis at third-party facilities located in Derabassi (Punjab) and other locations in India, rather than at company-owned production lines. The company runs a DSIR-recognised in-house R&D centre focused on process development, cost improvement of existing APIs and indigenous (in-house) development of key starting materials/raw materials to reduce import dependence.
Segments
- Active Pharmaceutical Ingredients (APIs) / bulk drugs
- API / bulk drug portfolio
- 17+ APIs across anticoagulant, anti-diabetic, antihypertensive, antibiotic, antihistamine & other therapeutic segments
- Manufacturing model
- Job-work manufacturing at third-party facilities in Derabassi (Punjab) and other locations in India
- R&D Centre
- DSIR-recognised in-house R&D facility at Village Bhondsi, Sohna, Gurugram (Regn. No. TU/IV-RD/4410/2021)
- Key starting materials (KSMs) developed in-house
- 9 (incl. Bilastine KSM, Fima KSM, Glycidyl phthalimide, TPI-BOC, INB-Acetoacetate)
- Plant certification
- GMP-certified by State FDA, Haryana
- Industry association memberships
- 5 (PHARMCIL, HEMS, CII, DCC, FOPE)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −40% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 28 | 30 | 38 | 24 | 34 | 30 | 27 | 21 |
| Expenses | 25 | 25 | 30 | 21 | 31 | 24 | 25 | 18 |
| Operating profit | 3 | 5 | 8 | 3 | 3 | 7 | 3 | 2 |
| Operating margin | 12.0% | 16.6% | 21.4% | 10.7% | 7.4% | 21.8% | 9.8% | 11.3% |
| Other income | 0 | 0 | 0 | 1 | -0 | 0 | 1 | 0 |
| Interest | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 4 | 6 | 1 | 1 | 5 | 2 | 0 |
| Tax rate | 15.7% | −27.3% | 68.6% | 13.0% | −7.4% | −7.7% | 79.0% | 26.5% |
| Net profit | 2 | 5 | 2 | 1 | 1 | 5 | 0 | 0 |
| EPS (₹ per share) | 0.34 | 0.97 | 0.42 | 0.13 | 0.22 | 1.15 | 0.08 | 0.08 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 129 | 105 | 119 | 115 |
| Expenses | 133 | 105 | 99 | 101 |
| Operating profit | -5 | -0 | 20 | 14 |
| Other income | 0 | 2 | 1 | 2 |
| Interest | 4 | 5 | 5 | 4 |
| Depreciation | 3 | 3 | 3 | 4 |
| Profit before tax | -12 | -7 | 14 | 8 |
| Net profit | -9 | -5 | 10 | 7 |
| Line item | Mar 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 1 | -4 | -1 | 5 | 7 | 13 |
| Borrowings | 53 | 44 | 39 | 33 | 36 | 35 |
| Other liabilities | 63 | 56 | 57 | 68 | 54 | 51 |
| Total liabilities | 121 | 100 | 99 | 111 | 101 | 103 |
| Fixed assets | 34 | 32 | 31 | 33 | 34 | 37 |
| Capital work in progress | 1 | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 87 | 68 | 68 | 78 | 68 | 66 |
| Total assets | 121 | 100 | 99 | 111 | 101 | 103 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 6 | 8 | -7 | 15 | 21 | 11 |
| Cash from investing | -14 | -1 | -3 | -1 | -5 | -8 |
| Cash from financing | 8 | -8 | 10 | -13 | -17 | -3 |
| Net cash flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -8 | 6 | -10 | 13 | 17 | 3 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 115 | 88 | 87 | 96 | 113 | 93 |
| Inventory days | 89 | 146 | 183 | 149 | 178 | 137 |
| Days payable | 116 | 159 | 177 | 194 | 260 | 220 |
| Cash conversion cycle | 88 | 76 | 93 | 51 | 31 | 10 |
| Working capital days | 53 | 31 | 16 | -30 | -22 | 5 |
| Return on capital employed | 16.0% | −2.0% | −12.0% | −4.0% | 42.0% | 25.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Promoters hold 74.94% as of Jun 2026; institutions added 0.00 pts since Mar 2026.
- Promoters 74.94%
- Domestic institutions 0.38%
- Public 24.68%
Who is on the register
Named in the Jun 2026 filing
Every holder of KIMIA BIOSCIENCES LIMITED above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 74.94% | unchanged | |
| 4.33% | unchanged | |
| 4.25% | unchanged | |
| 4.11% | unchanged | |
| 3.33% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for KIMIA BIOSCIENCES LIMITED
Free account: one company. Everything above stays public.
Write why you follow KIMIA BIOSCIENCES LIMITED and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse KIMIA BIOSCIENCES LIMITED
Guides on how to read this kind of business and the numbers that matter.